Novo Nordisk has expanded its artificial-intelligence strategy through a collaboration with Anthropic that will test Claude Science in pharmaceutical R&D, adding another AI partner as the drugmaker seeks faster research productivity amid intensifying competitive pressure.
Anthropic’s new Model Hardware Standard allows artificial-intelligence agents to control microscopes, liquid handlers, robotic arms and other physical laboratory equipment, creating a path toward autonomous drug-discovery laboratories capable of designing, running and adjusting experiments around the clock.
ICON and Anthropic will build Claude-powered clinical trial tools inside Orbis, targeting site selection, enrolment risk and protocol design.
Bristol Myers Squibb is moving AI from pilots to enterprise scale. Claude’s real test is governance, data trust and drug development impact.